Erratum: Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: Comparison of skeletal-related events and symptomatic skeletal events [Ann Oncol, 26, (2015), 368-375], doi: 10.1093/annonc/mdu519;Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: Comparison of skeletal-related events and symptomatic skeletal events

Annals of Oncology

Volumn 26, Issue 2, 2015, Pages 368-374

  Smith, Matthew R ^a   Coleman, R E ^b   Klotz, L ^c   Pittman, K ^d   Milecki, P ^e,f   Ng, S ^g   Chi, K N ^h   Balakumaran, A ⁱ   Wei, R ⁱ   Wang, H ⁱ   Braun, A ⁱ   Fizazi, K ^j  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b Academic Unit of Clinical Oncology   (United Kingdom)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d QUEEN ELIZABETH HOSPITAL   (Australia)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f GREATER POLAND CANCER CENTRE   (Poland)

^g ST JOHN OF GOD HOSPITAL   (Australia)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁱ AMGEN INC   (United States)

^j INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Denosumab; Phase III; Prostate cancer; Skeletal related events; Symptomatic skeletal events; Zoledronic acid

Indexed keywords

DENOSUMAB; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; ARTICLE; BONE DISEASE; BONE METASTASIS; BONE RADIATION; BRIEF PAIN INVENTORY; CANCER PAIN; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; PARTIAL BODY RADIATION; PATHOLOGIC FRACTURE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SKELETAL RELATED EVENT; SPINAL CORD COMPRESSION; SYMPTOMATIC RELATED EVENT; AGED; BONE TUMOR; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DENOSUMAB; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84925339649     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv155     Document Type: Erratum

References (21)

1. Saylor PJ, Armstrong AJ, Fizazi K et al. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 2013; 63: 309-320.
2. Bubendorf L, Schopfer A, Wagner U et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31: 578-583.
3. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80: 1588-1594.
4. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s-6249s.
5. Weinfurt KP, Li Y, Castel LD et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005; 16: 579-584.
6. Aredia® ( pamidronate disodium). Full Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corp, 2012.
7. Zometa® (zoledronic acid). Full Prescribing Information. East Hanover, NJ: Novartis Pharmaceutical Corp, 2014.
8. XGEVA® (denosumab). Full Prescribing Information. Thousand Oaks, CA: Amgen Inc., 2013.
9. European Medicines Agency (EMA). Zometa® (zoledronic acid). Summary of Product Characteristics. West Sussex, UK: Novartis Europharm Limited, 2014.
10. European Medicines Agency (EMA). XGEVA® (denosumab). Summary of Product Characteristics. Breda, The Netherlands: Amgen Europe B.V., 2014.
11. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822.
12. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223.
13. Sartor O, Coleman R, Nilsson S et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014; 15: 738-746.
14. James ND, Pirrie S, Brown JE et al. Clinical outcomes in patients with castraterefractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). J Clin Oncol 2013; 31: abstr LBA5000.
15. von Moos R, Body JJ, Egerdie B et al. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer 2013; 21: 3497-3507.
16. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
17. Lipton A, Fizazi K, Stopeck AT et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48: 3082-3092.
18. Henry D, Vadhan-Raj S, Hirsh V et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer 2014; 22: 679-687.
19. Patrick D, Cleeland C, Fallowfield L et al. Denosumab or zoledronic acid (ZA) therapy on pain interference and cancer-specific quality of life (CSQoL) in patients with castrate-resistant prostate cancer (CRPC) and bone metastases (BM). J Clin Oncol 2014; 32: abstr 12.
20. Body JJ, Lipton A, Gralow J et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res 2010; 25: 440-446.
21. Fizazi K, Bosserman L, Gao G et al. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009; 182: 509-515; discussion 515-506.